DUBLIN, Nov. 14, 2022 /PRNewswire/ -- The "Cardiac Marker Testing Market by Product (Reagent, Instrument), Component (Troponin I & T, CK-MB, Myoglobin, BNP, hs-CRP), Disease (Myocardial Infarction, Congestive Heart Failure, Atheresclerosis), Enduser (Lab, PoC, Academia) - Global Forecast to 2027" report has been added to ResearchAndMarkets.com's offering.
The global cardiac marker testing market is projected to reach USD 7.7 Billion by 2027 from USD 5.0 Billion in 2022, at a CAGR of 8.7% during the forecast period.
Troponin I and T estimated held the largest share of cardiac marker testing market in 2021, by Biomarker Type Factors such as high sensitivity and specificity, long elevation time (rises over 4-8 hours, peaks at 10-24 hours, and declines over ten days), and rapid prediction of outcomes are driving the growth of this segment. In addition, lab technicians are more familiar with the use of these markers as compared to other biomarkers
Laboratory testing facilities segment accounted for the largest share of the cardiac marker testing market in 2021, by End user
Based on end users, the cardiac marker testing market is segmented into laboratory testing facilities, academic institutes, and point-of-care testing facilities. In 2021, the laboratory testing facilities segment accounted for the largest share of 61.4% of the global cardiac marker testing market. Factors such as high testing throughput, better sensitivity & diagnostic accuracy compared to POC testing, and high preference for laboratory testing over POCT testing are driving the growth of this segment.
The Asia Pacific market to grow at the highest CAGR during the forecast period
The cardiac marker testing market is segmented into five major regions, namely, North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Asia Pacific is estimated to be the fastest-growing market for cardiac marker testing during the forecast period.
The Asia Pacific market is driven due rising growing investments by government agencies in emerging countries of Asia Pacific for the improvement of healthcare infrastructure, growing number of independent clinical laboratories, presence of large patient population, and strategies adopted by players to increase their cardiac testing product reach in Asia Pacific.
4.1 Cardiac Marker Testing Market Overview
4.3 Europe: Cardiac Marker Testing Market, by End-user and Region
4.4 Cardiac Marker Testing Market: Geographical Snapshot
5.2.1.2 Increasing Geriatric Population and Subsequent Rise in Heart Conditions Worldwide
5.2.1.3 Growing Research & Funding Initiatives from Public & Private Organizations
5.2.1.4 Rising Clinical Studies for Identification of Novel Cardiac Biomarkers
5.2.2.1 Technical Issues Related to Sample Collection & Storage
5.2.2.2 Unfavorable Regulatory Processes and Limited Reimbursement Structure
5.2.3.3 Emerging Markets Offer High-Growth Opportunities
5.2.4.1 Challenges Associated with Biomarker Assay Validation
5.4 Reimbursement Scenario
5.6 Supply Chain Analysis
5.7 Ecosystem Analysis: Parent Market (In Vitro Diagnostics)
5.8.1 Average Selling Price of Cardiac Market Test Kits by Key Players
5.9 Porter's Five Forces Analysis
5.11 Key Conferences & Events (2022-2024)
5.13 Trends/Disruptions Impacting Customers' Businesses
5.14 Key Stakeholders & Buying Criteria
5.15 Key Buying Criteria by End-users
6 Cardiac Marker Testing Market, by Product
6.2.1 Rising Volume of Diagnostic Tests to Drive Demand
6.3.1.1 Most Preferred Method for Quantification of Cardiac Biomarkers to Drive Segment Growth
6.3.2.1 Demand for Stable and Safer Reagents to Support Market Growth
6.3.3.1 Long Shelf Life and Ease of Use to Propel Segment Growth
6.3.4 Immunochromatography
6.3.4.1 Increasing Use in Point-Of-Care Settings to Drive Adoption of this Technique
7.2.1 High Sensitivity and Specificity in Detection of CVD to Drive Market 7.4.1 Use of Bnp with Other Cardiac Markers to Enhance Utilization
7.5.1 Rapid Increase and Normalization Associated with Myoglobin to Drive Market
7.6.1 Ability of Hscrp Tests to Accurately Measure Low Levels of Crp to Support Market Growth 8 Cardiac Marker Testing Market, by Disease
8.2.1 Availability of High-Sensitivity Biomarkers for Detection of Mi to Drive Market 8.3.1 Increasing Use of Multi-Marker Testing to Support Market Growth
8.4.1 Increasing Incidence of Risk Factors Associated with Acs to Drive Adoption of Cardiac Markers 8.5.1 High Prevalence of Atherosclerosis to Drive Uptake of Cardiac Markers 8.6.1 Multiple Complications Caused by Ischemia to Drive Adoption of Diagnostic Tests 9 Cardiac Marker Testing Market, by End-user
9.2 Laboratory Testing Facilities
9.2.1.1 Emergency Patient Care and Early Diagnosis Associated with In-House Labs to Drive Market
9.2.2.1 Affordable and Time-Efficient Services Associated with Reference Laboratories to Support Market Growth
9.2.3 Contract Testing Laboratories
9.2.3.1 Ability to Perform Multiple Tests and Cover Wider Matrices to Support Market Growth
9.3.1 Continuous Research & Development of Novel Biomarkers to Drive Market
9.4.1 Early Detection and Lower Turnaround Time to Drive Market
10 Cardiac Marker Testing Market, by Region
11.2 Strategies Adopted by Key Players/Right to Win
11.4 Cardiac Marker Testing Market: Market Share Analysis, by Key Player (2021)
11.5 Company Evaluation Quadrant for Major Players (As of 2021)
11.6 Company Evaluation Quadrant (SMEs/Startups)
11.6.1 Progressive Companies
11.6.2 Responsive Companies
11.8 Competitive Scenario (2019-2022)
11.8.1 Product Launches & Approvals
11.8.3 Other Developments
12.1.19 Response Biomedical
For more information about this report visit https://www.researchandmarkets.com/r/8hld8w
Laura Wood, Senior Manager
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Fax (outside U.S.): +353-1-481-1716
Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg